Qurient Announces Collaboration Agreement with MSD to Evaluate Selective Triple Inhibitor Q702 in Combination With KEYTRUDA® (pembrolizumab)
- Q702 is a novel, orally available triple kinase inhibitor that selectively targets Axl, Mer,…
- Q702 is a novel, orally available triple kinase inhibitor that selectively targets Axl, Mer,…
RMIT University adopts HPE GreenLake to meet increasing demand for online learning and growth of…
MACAU, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Studio City International Holdings Limited (NYSE: MSC) (“Studio…
-- Zai Lab obtains exclusive rights to develop and commercialize BLU-945 and BLU-701 in Greater…
WALL, N.J., Nov. 09, 2021 (GLOBE NEWSWIRE) -- BIO-key International, Inc. (NASDAQ: BKYI), an innovative…
Revenue up 34% year-over-year to $49.9M, GAAP operating income of $0.9 million and Adjusted EBITDA…
Zai Lab obtains exclusive rights to develop and commercialize KarXT in Greater China Karuna to…
-- Broad Product Pipeline Expands Both Vertically and Horizontally with Three New Potential First-in-Class or…
12.4% Year-Over-Year Revenue Growth 56.4% Year-Over-Year Subscription Revenue Growth $16.5 million in Net Cash Provided…
DENVER, Nov. 09, 2021 (GLOBE NEWSWIRE) -- NewAge, Inc. (Nasdaq: NBEV), the Colorado-based direct-to-consumer (D2C)…